Pediatric DRV/r (pDRV/r) FAQs
This document is meant to answer some of the most common questions that surround pediatric darunavir/ritonavir 120/20mg (pDRV/r) - a new...
top of page
A framework to support new product introduction in national health systems
Resource Library
- Sep 6
Pediatric DRV/r (pDRV/r) Product Profile
This product profile provides a clinical overview of the best-in-class protease inhibitor (PI) formulated in a fixed-dose combination...
23
- Jun 7
2023 CHAI HIV Mid-Year Market Memo
Introducing the seventh edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...
40
- Jun 5
Pediatric ALD (pALD) FAQs
This document is meant to answer some of the most common questions surround the fixed-dose combination of pediatric...
68
- May 30
pALD Product Profile
This product profile provides a clinical overview of the fixed-dose combination of pediatric abacavir/lamivudine/ dolutegravir 60/30/5 mg...
193
- May 30
Pediatric Treatment Optimization Roadmap
This treatment optimization roadmap is a resource for Ministries of Health and partner organizations. It offers a summary of pediatric...
146
- May 24
GAP-f pALD Introduction and Rollout Planning Considerations for National Programmes
The GAP-f pDTG task team has developed a brief outlining product introduction and rollout considerations for national programmes when...
262
- May 4
The Transitioning Children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study
The Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) Study was conducted in Benin, Nigeria, and Uganda....
168
- Dec 16, 2022
2022 HIV Market Report
CHAI is pleased to release the 13th issue of our annual HIV market report. This report provides a detailed look at the complex,...
89
- May 31, 2022
2022 CHAI HIV Mid-Year Market Memo
Introducing the sixth edition of CHAI’s HIV Mid-Year Market Memo, a brief that covers the latest trends in the HIV space in low- and...
214
- May 24, 2022
GAP-f pDTG Implementation Considerations for National Programmes
In mid-2021, national HIV programmes began to transition treatment for children living with HIV to dolutegravir (DTG) 10 ...
337
- Apr 13, 2022
Adult DRV/r (400/50mg) FAQs for Communities and PLHIV
CHAI developed these frequently asked questions (FAQs) to lay out information for communities and PLHIV on the subject of DRV/r (400/50...
157
- Mar 17, 2022
Adult DRV/r (400/50mg) Clinical Action Memo
Darunavir (DRV) is a best-in-class protease inhibitor (PI) used in combination with other antiretroviral (ARV) drugs for the...
179
- Mar 17, 2022
CHAI DRV/r 2L Product Profile
A presentation with the latest information on DRV/r (400/50mg) and considerations for adult second line treatment optimization.
137
- Mar 17, 2022
DRV/r (400/50mg) FAQs
CHAI developed these frequently asked questions (FAQs) to lay out information for national HIV programs considering the adoption and...
68
- Nov 16, 2021
2021 Regional HIV Market Briefs
Regional HIV Market Briefs, produced by the CHAI HIV Access Program, provide the latest region-specific market intelligence on ART...
28
- Oct 12, 2021
Pediatric DTG FAQs
This document is meant to assist national HIV programs in pDTG adoption. This document provides a summary of pDTG, including advantages...
66
- Oct 12, 2021
2021 HIV Market Report
CHAI is pleased to release the 12th issue of our annual HIV market report. This report provides a detailed look at the complex,...
47
- Oct 12, 2021
CHAI Pediatric DTG Product Profile
This product profile provides a clinical overview of pediatric DTG, market updates and implementation considerations, and provides...
121
- Oct 11, 2021
Pediatric DTG Implementation Memo (English, French)
CHAI has developed this memo to lay out information for national HIV programs considering the introduction of pediatric...
78
bottom of page